Direct acting oral anticoagulants have a lower risk of major bleeding than warfarin and clinicians have had options for controlling major bleeds for several years. That’s not the message patients have heard, though.
Dabigatran, apixaban, edoxaban and rivaroxaban all have FDA approval for use to reduce the risk of stroke and blood clots in patients with nonvalvular atrial fibrillation and treatment of deep vein thrombosis and pulmonary embolism. Dabigatran, apixaban and rivaroxaban are also indicated for the prevention of blood clots after hip or knee replacement surgery.
PALO ALTO, CA — Ten years ago choosing an anticoagulation therapy boiled down to Warfarin or—Warfarin. Today, physicians and patients in the VA and elsewhere have more anticoagulant choices than ever. and those newer options have largely displaced Warfarin for many indications.
IOWA CITY, IA — About one-third of VA patients have three or more chronic conditions.1 Ironically, for many of them, that complexity makes choosing between warfarin and a direct acting oral anticoagulant easier.